CORRECTION





Correction: miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma

Yi Cai^{1,2} · Wenda Wang¹ · Hao Guo¹ · Hanzhong Li¹ · Yu Xiao³ · Yushi Zhang¹

Published online: 18 October 2018

© United States & Canadian Academy of Pathology 2018

Correction to: *Laboratory Investigation* **98**, 856–870 (2018); https://doi.org/10.1038/s41374-018-0051-6; published online 14 March 2018

Following the publication of this article, the authors noticed an error in Fig. 5c. In the miR-132-3p mimics. This does not affect the results and conclusions of the article. The correct version of Fig. 5 can be found below.

Fig. 5 The role of miR-9-5p, miR-124-3p, and miR-132-3p in the regulation of proliferation and apoptosis in Tsc2^{-/-} cells. **a** CCK-8 assays were performed 24, 48, 72, and 96 h after the transfection of Tsc2^{-/-} cells with miR-9-5p, miR-124-3p, or miR-132-3p mimics or the scrambled control. **b** CCK-8 assays were performed 24, 48, 72, and 96 h after the transfection of Tsc2^{-/-} cells with miR-9-5p, miR-124-3p, or miR-132-3p inhibitors or the negative control. **c**, **d** Tsc2^{-/-} cells were transfected with equal doses of miR-9-5p, miR-124-3p, or miR-132-3p mimics or the scrambled control. The cell apoptosis profiles were analyzed by flow cytometry. The bi-parametric histogram shows cells in early (bottom right quadrant) and late (top right quadrant) apoptotic states. Viable cells are double negative (bottom left quadrant). **c** Representative image. **d** Quantitative analysis. **e**, **f** Tsc2^{-/-} cells were transfected with equal doses of miR-9-5p, miR-124-3p, or miR-132-3p inhibitors or the negative control. The cell apoptosis profiles were analyzed by flow cytometry. The bi-parametric histogram shows cells in early (bottom right quadrant) and late (top right quadrant) apoptotic states. Viable cells are double negative (bottom left quadrant). **e** Representative image. **f** Quantitative analysis

[✓] Yushi Zhang zhangyushi2014@126.com

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730 Beijing, China

Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City 410008 Hunan Province, China

Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730 Beijing, China

444 Y. Cai et al.

